IL266738B2 - Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer - Google Patents

Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer

Info

Publication number
IL266738B2
IL266738B2 IL266738A IL26673819A IL266738B2 IL 266738 B2 IL266738 B2 IL 266738B2 IL 266738 A IL266738 A IL 266738A IL 26673819 A IL26673819 A IL 26673819A IL 266738 B2 IL266738 B2 IL 266738B2
Authority
IL
Israel
Prior art keywords
antibody
antigen
binding fragment
seq
binding
Prior art date
Application number
IL266738A
Other languages
English (en)
Hebrew (he)
Other versions
IL266738A (en
IL266738B1 (en
Inventor
Peter Ellmark
Sara Fritzell
Christina Furebring
Jessica Petersson
Anna Sall
Karin Enell Smith
Laura Varas
Schantz Laura Von
Niina Veitonmaki
Original Assignee
Alligator Bioscience Ab
Peter Ellmark
Sara Fritzell
Christina Furebring
Jessica Petersson
Anna Sall
Karin Enell Smith
Laura Varas
Schantz Laura Von
Niina Veitonmaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience Ab, Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Schantz Laura Von, Niina Veitonmaki filed Critical Alligator Bioscience Ab
Publication of IL266738A publication Critical patent/IL266738A/en
Publication of IL266738B1 publication Critical patent/IL266738B1/en
Publication of IL266738B2 publication Critical patent/IL266738B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL266738A 2016-11-21 2017-11-21 Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer IL266738B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619648.7A GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof
PCT/EP2017/079930 WO2018091740A2 (en) 2016-11-21 2017-11-21 Novel antibodies and uses thereof

Publications (3)

Publication Number Publication Date
IL266738A IL266738A (en) 2019-07-31
IL266738B1 IL266738B1 (en) 2024-02-01
IL266738B2 true IL266738B2 (en) 2024-06-01

Family

ID=57993708

Family Applications (1)

Application Number Title Priority Date Filing Date
IL266738A IL266738B2 (en) 2016-11-21 2017-11-21 Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer

Country Status (14)

Country Link
US (3) US11535678B2 (enExample)
EP (1) EP3541844A2 (enExample)
JP (1) JP7068303B2 (enExample)
KR (1) KR102679632B1 (enExample)
CN (1) CN109963873B (enExample)
AU (1) AU2017360094B2 (enExample)
BR (1) BR112019010265A2 (enExample)
CA (1) CA3044339A1 (enExample)
GB (1) GB201619648D0 (enExample)
IL (1) IL266738B2 (enExample)
MX (1) MX2019005911A (enExample)
NZ (1) NZ754051A (enExample)
RU (1) RU2019116624A (enExample)
WO (1) WO2018091740A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
WO2018127787A1 (en) * 2017-01-06 2018-07-12 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
PE20200839A1 (es) 2017-08-01 2020-08-13 Lilly Co Eli Anticuerpos anti-cd137
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
CN112020517B (zh) 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
JP7387743B2 (ja) * 2018-09-12 2023-11-28 ユーカー（ベンジン） バイオファーマ カンパニー，リミテッド 抗ｔｎｆｒｓｆ９抗体及びその使用
CN120098128A (zh) * 2019-01-02 2025-06-06 Qlsf生物治疗药物公司 Cd137激动剂抗体及其用途
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CN118791614A (zh) 2019-06-26 2024-10-18 圆祥生技股份有限公司 T细胞活化抗体
JP7432716B2 (ja) * 2019-11-13 2024-02-16 合肥瀚科邁博生物技術有限公司 ヒト４－１ｂｂに結合可能な分子及びその応用
US11396647B2 (en) 2020-01-07 2022-07-26 Board Of Regents, The University Of Texas System Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
EP4096789A4 (en) 2020-01-29 2023-10-11 Board of Regents, The University of Texas System USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS
CN115362270A (zh) 2020-01-29 2022-11-18 得克萨斯州大学系统董事会 Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途
BR112022016491A2 (pt) * 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
JP2023531042A (ja) * 2020-06-30 2023-07-20 諾納生物（蘇州）有限公司 ４－１ｂｂ結合タンパク質及びその用途
JP7744991B2 (ja) * 2021-01-08 2025-09-26 北京韓美薬品有限公司 ４－１ｂｂと特異的に結合する抗体及びその抗原結合フラグメント
US20240287199A1 (en) 2021-06-18 2024-08-29 Alligator Bioscience Ab Novel combination therapies and uses thereof
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
GB2629959A (en) * 2021-12-29 2024-11-13 Curateq Biologics Private Ltd C1Q binding assay
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025531938A (ja) * 2022-09-22 2025-09-25 アブリンク バイオテック カンパニー リミテッド 抗４－１ｂｂナノボディ、その製造及び使用
CN116041517B (zh) * 2022-12-19 2025-02-25 首都医科大学附属北京胸科医院 一种抗人cd137抗体及其应用
CN116162162B (zh) * 2022-12-19 2025-05-27 首都医科大学附属北京胸科医院 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用
CN116271009A (zh) * 2023-01-13 2023-06-23 深圳市乐土生物医药有限公司 含有CpG佐剂和4-1BB抗体的药物组合物及其用途
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016134358A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
TWI423814B (zh) 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
US11008396B2 (en) 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016134358A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOLANOS-MATEO, ELIXABET, ET AL., FOCUSING AND SUSTAINING THE ANTITUMOR CTL EFFECTOR KILLER RESPONSE BY AGONIST ANTI-CD137 MAB., 6 November 2014 (2014-11-06) *
PETERS, SHIRLEY J., ET AL., ENGINEERING AN IMPROVED IGG4 MOLECULE WITH REDUCED DISULFIDE BOND HETEROGENEITY AND INCREASED FAB DOMAIN THERMAL STABILITY., 13 July 2012 (2012-07-13) *
RYAN, JOSEPH M., ET AL., ENHANCING THE SAFETY OF ANTIBODY-BASED IMMUNOMODULATORY CANCER THERAPY WITHOUT COMPROMISING THERAPEUTIC BENEFIT: CAN WE HAVE OUR CAKE AND EAT IT TOO?., 25 February 2016 (2016-02-25) *
SANCHEZ?PAULETE, ALFONSO R., ET AL., DECIPHERING CD137 (4?1BB) SIGNALING IN T?CELL COSTIMULATION FOR TRANSLATION INTO SUCCESSFUL CANCER IMMUNOTHERAPY., 1 March 2016 (2016-03-01) *
SEGAL, NEIL H., ET AL., RESULTS FROM AN INTEGRATED SAFETY ANALYSIS OF URELUMAB, AN AGONIST ANTI-CD137 MONOCLONAL ANTIBODYINTEGRATED SAFETY ANALYSIS OF URELUMAB., 18 October 2016 (2016-10-18) *
VINAY, DASS S., AND BYOUNG S. KWON., THERAPEUTIC POTENTIAL OF ANTI-CD137 (4-1BB) MONOCLONAL ANTIBODIES., 3 March 2016 (2016-03-03) *

Also Published As

Publication number Publication date
EP3541844A2 (en) 2019-09-25
IL266738A (en) 2019-07-31
BR112019010265A2 (pt) 2019-09-17
US12509526B2 (en) 2025-12-30
AU2017360094B2 (en) 2024-12-12
US10689454B2 (en) 2020-06-23
IL266738B1 (en) 2024-02-01
RU2019116624A (ru) 2020-12-21
GB201619648D0 (en) 2017-01-04
AU2017360094A1 (en) 2019-06-20
CN109963873A (zh) 2019-07-02
NZ754051A (en) 2023-05-26
KR102679632B1 (ko) 2024-06-28
MX2019005911A (es) 2019-07-08
RU2019116624A3 (enExample) 2021-01-29
US20190352411A1 (en) 2019-11-21
KR20190086691A (ko) 2019-07-23
JP2020501531A (ja) 2020-01-23
CA3044339A1 (en) 2018-05-24
WO2018091740A3 (en) 2018-06-28
US20190352414A1 (en) 2019-11-21
US20230295325A1 (en) 2023-09-21
JP7068303B2 (ja) 2022-05-16
WO2018091740A2 (en) 2018-05-24
CN109963873B (zh) 2023-12-26
US11535678B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
US12509526B2 (en) Anti-CD137 antibodies and uses thereof
US12173082B2 (en) Bispecific polypeptides against CD137
US20190161555A1 (en) Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen
KR20220167342A (ko) 변형된 중쇄 불변 영역을 포함하는 항체
BR112017002342A2 (en) new antibodies and their uses
US20220073635A1 (en) Novel polypeptides
US20220064325A1 (en) Novel polypeptides
WO2024231251A1 (en) Anti-il1rap antibodies
JP2024522234A (ja) 新規な併用療法及びその使用
WO2024023118A1 (en) Novel dosages of anti-cd137 antibody
WO2024023120A1 (en) Novel dosages of anti-cd137 antibody
HK40003232A (en) Novel bispecific polypeptides against cd137
HK40004686B (en) Novel bispecific polypeptides against cd137